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“Regulatory Bioinformatics” strives to develop and implement a standardized and transparent bio-
informatic framework to support the implementation of existing and emerging technologies in regula-
tory decision-making. It has great potential to improve public health through the development and use
of clinically important medical products and tools to manage the safety of the food supply. However, the
application of regulatory bioinformatics also poses new challenges and requires new knowledge and skill
sets. In the latest Global Coalition on Regulatory Science Research (GCRSR) governed conference, Global
Summit on Regulatory Science (GSRS2015), regulatory bioinformatics principles were presented with
respect to global trends, initiatives and case studies. The discussion revealed that datasets, analytical
tools, skills and expertise are rapidly developing, in many cases via large international collaborative
consortia. It also revealed that signiﬁcant research is still required to realize the potential applications of
regulatory bioinformatics. While there is signiﬁcant excitement in the possibilities offered by precision
medicine to enhance treatments of serious and/or complex diseases, there is a clear need for further
development of mechanisms to securely store, curate and share data, integrate databases, and stan-
dardized quality control and data analysis procedures. A greater understanding of the biological signif-
icance of the data is also required to fully exploit vast datasets that are becoming available. The
application of bioinformatics in the microbiological risk analysis paradigm is delivering clear beneﬁts
both for the investigation of food borne pathogens and for decision making on clinically important
treatments. It is recognized that regulatory bioinformatics will have many beneﬁcial applications by
ensuring high quality data, validated tools and standardized processes, which will help inform the
regulatory science community of the requirements necessary to ensure the safe introduction and
effective use of these applications.
Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).1. Introduction
Emerging life-science technologies offer major opportunities to.au (M.J. Healy), weida.tong@
Ostroff), hans-georg.eichler@
a.eu (A. Patak), margaret.
bert.deluyker@efsa.europa.eu
r).
access article under the CC BY liceimprove public health through the development and use of inno-
vative medical products and by improving the safety of the food
supply. However, these technologies often utilize and generate
large amounts of data. In order to effectively use these data sets for
regulatory purposes, policies, strategies and approaches to curate,
analyse and interpret the data must be development. Such efforts,
which can be thought of as “regulatory bioinformatics” can
strengthen the scientiﬁc evidence base and produce tools to sup-
port, improve, and enhance the efﬁciency of regulatory decision
making. Initiatives to develop regulatory bioinformatics capabil-
ities are underway globally that aim to maximize the healthnse (http://creativecommons.org/licenses/by/4.0/).
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tomorrow.
Bioinformatics is considered a priority area within the regula-
tory science agenda (http://www.fda.gov/ScienceResearch/
SpecialTopics/RegulatoryScience/ucm228131.htm). To move this
agenda forward requires enhancing global scientiﬁc capacity and
cooperation among academia, regulatory agencies and industry.
One mechanism to accomplish this goal was the establishment in
2013 of the Global Coalition for Regulatory Science Research
(GCRSR), an international collaboration that aims to build knowl-
edge, to promote the development of regulatory science, and to
identify research needs to support regulatory decision making. A
major focus is establishing best practices to understand and inter-
pret data from innovative technologies and facilitate the translation
of basic science innovation into regulatory application (Tong et al.,
2015).
The GCRSR consists of representative governmental agencies
that regulate food and medical products in many countries (Tong
et al., 2015). Its mission is to communicate, among the global re-
searchers/regulators, current advances in science and their poten-
tial to impact the global regulatory process. Even before the
coalition was formally established in 2013, GCRSR began holding
annual conferences, named Global Summit on Regulatory Science
(GSRS) to facilitate scientiﬁc exchanges and enhanced under-
standing about emerging technologies and their potential appli-
cation in regulatory science (Tong et al., 2015; Howard et al., 2014;
Miller et al., 2013; Slikker et al., 2012). Each of the ﬁve conferences
since 2011 has focused on a speciﬁc topic in the context of regu-
latory research. The two most recent conferences focused on
nanotechnology in 2013 (Howard et al., 2014) and on regulatory
genomics in 2014 (Tong et al., 2015). At both of these conferences,
the crucial role of bioinformatics for successful regulation of
nanotechnology and genomics was readily apparent. Therefore, it
was decided that the theme of the 2015 conference (GSRS2015)
would be “regulatory bioinformatics.” This meeting was held on
October 12e13, 2015 at the headquarters of the European Food
Safety Authority in Parma, Italy (http://www.fda.gov/AboutFDA/
CentersOfﬁces/OC/OfﬁceofScientiﬁcandMedicalPrograms/NCTR/
WhatWeDo/).
“Regulatory bioinformatics” strives to develop and implement a
standardized and transparent bioinformatic framework to support
the implementation of existing and emerging technologies in reg-
ulatory decision-making. As shown in Fig. 1, GSRS2015 explored a
range of applications of regulatory bioinformatics in the develop-
ment and use of medical products and as tools to manage the safety
of the food supply. These examples illustrate the potential beneﬁts
of the technologies, highlight areas of research and development,
and the novel approaches required to fully realize these beneﬁts.
These examples also reveal the variable state of development of
applications. In the drug development arena, next generation
sequencing (NGS) has proven to be an excellent discovery tool, but
improvements are needed in bioinformatics to use the enormous
amount of data generated by NGS for beneﬁcial clinical applica-
tions. In contrast, several applications using different and large
datasets within the microbiological risk analysis framework in the
drug and food safety ﬁelds are delivering clear beneﬁts. In the
following sections, we summarize key discussions from GSRS2015
on these topics depicted in Fig. 1.
2. Precision medicine, next-generation sequencing and
regulatory application
Technologies such as NGS, when combined with bioinformatics
analysis, have the potential to revolutionize the treatment of dis-
eases and the evaluation of drug safety. NGS enables humangenomes to be sequenced rapidly and cost effectively, and tools are
now available for analysing the consequent large datasets,
providing a mechanism for treating patients individually to
enhance the health outcome as well as improving the success rate
in the development of new therapeutics. Individualized treatment
of patients (personalizedmedicine) takes into account their genetic
variation, environment and lifestyle. Several countries/regions are
implementing programs to support the application of precision
medicine (Winship, 2015). The United States is implementing the
multifaceted Precision Medicine Initiative to develop high quality,
curated databases and interoperable standards and requirements
that address privacy and enable secure exchange of data across
systems; to determine genomic drivers of diseases such as cancer
and identify appropriate biomarkers and develop more effective
treatments; and improve understanding of the environmental,
genetic, biochemical and other factors predictive of disease risk,
response to therapy, and disease outcomes (Collins and Varmus,
2015).
The new approaches required to identify effective treatments at
the individual level, classify diseases and the analytical tools
needed to effectively deliver personalized medicine are illustrated
by the transition from therapies that target individual mutations to
applied systems that address the complexity of diseases such as
cancers (Klauschen et al., 2014). Routine mutational proﬁling in
cancer diagnostics in concert with an increasing availability of
drugs targeting speciﬁc genetic alterations in tumors have started
to transform oncology. However, current targeted approaches that
are mostly monotherapies against single actionable mutations
show variable clinical response in most patients even with the
identical mutations and resistance develops frequently during
therapy.
This is likely due to the mutational complexity observed in most
cancers that may induce multiple oncogenic mechanisms (Heim
et al., 2014). There is currently a lack of information about the
clinical relevance of the many mutations found within tumors.
Moreover, actionable mutations are normally present in only a
minor fraction of the tumors, which makes the recruitment of a
sufﬁcient number of suitable patients exceedingly difﬁcult for drug
combinations because of the high combinatorial complexity.
Therefore current clinical trial design strategies need to be recon-
sidered to solve the combinatorial complexity problem.
Novel experimental approaches that integrate genomic with
dynamic proteomic proﬁling and computational modeling facilitate
the analysis of the functional effects of the observed mutational
proﬁles. This allows for a substantial reduction of the mutational
complexity and identiﬁcation of driver mutations that propose
combination therapies for individual patients. This approach may
serve as the basis for future novel clinical design strategies that no
longer only test speciﬁc drugs for a particularmolecular cancer type
but also evaluate the capability of systems biological approaches to
predict optimal targeted (combination) therapies for individual
patients.
One of the key issues in applying NGS/bioinformatics in regu-
latory decision making is ensuring the accuracy and quality of in-
formation. To gain a full understanding of this issue, the United
States has created a community research and development portal
that allows for testing, piloting, and validating existing and new
bioinformatics approaches to NGS processing (PrecisionFDA,
https://precision.fda.gov). PrecisionFDA is focused on software to
evaluate and characterize NGS applications within an open-source
cloud infrastructure and is considering secure storage of human
genomes, storage and sharing software for NGS, reference genomes
for use in identifying variants and how to use ethnically diverse and
admixed genomes in validating annotation tools. China is also
implementing an initiative to speed the development of precision
Fig. 1. Overview of regulatory bioinformatics and its associated impact on regulatory decision-making.
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of 'omics techniques (genomics, transcriptomics, proteomics, and
metabolomics); consider phenotypic information from sources
such as electronic health records, clinical information, survival data
and the Human Phenomics Project; and develop big data tools that
address data quality, standardization, data mining and standard
operating procedures. China's approach to precision medicine in-
cludes diagnosis, prognosis, therapy, monitoring and prevention
and is focused on ten types of cancers, type 2 diabetes and various
rare diseases.
Many of the current issues with NGS resemble challenges faced
a decade ago when microarray technologies were the principle tool
for gene expression assessment. At that time, a number of FDA
efforts were initiated to utilize and evaluate these technologies
within inter-center and cross-community collaborations. Examples
include the FDA's Voluntary eXploratory Data Submission program
to develop standards and bioinformatics solutions to receive and
evaluate these new data in the review process (Goodsaid et al.,
2010), and the FDA led community wide MicroArray Quality Con-
trol (MAQC) consortium to address the quality control and proper
use of these new genomic methodologies (e.g. SEQC/MAQC SEQC/
MAQC-III Consortium, 2014). Global partnerships and cooperation
among the regulatory agencies of different countries are essential
for building consensus and best practices to expedite the trans-
lation from the exploratory nature of NGS to regulatory application.3. Drugs and biologics
A novel approach to the post market monitoring of the safety of
drugs and biologics, making use of large datasets of patient infor-
mation relating to insurance claims, diagnostic and clinical pro-
cedures and patient information held by insurance companies,
hospitals and government has been explored by Japan, amongst
other countries. The incorporation of electronic health records into
drug safety assessments can overcome some of the weaknesses of
conventional approaches (under reporting of adverse events, dif-
ﬁculty in attributing adverse events to drug effects) by allowing
assessment of information from millions of patients (https://www.
pmda.go.jp/english/safety/surveillance-analysis/0001.html).
The pharmacoepidemiological methodology of using electronichealth information for regulatory decision making on drug safety
has been conducted in a number of pilot studies that tested well
characterized safety issues (e.g., the concomitant use of sitagliptin
and sulfonylurea). The approach is being progressively imple-
mented with the aim to use it in regulatory post-marketing safety
assessments and re-examination of approved drugs. Successful
implementation requires a medical information database with data
standardization and quality assurance procedures to integrate vast
quantities of patient records from different clinical settings with
real time synchronization of information. To reduce the risk of
biased information, a robust sample of hospitals need to partici-
pate, and currently there is no link between hospital information
for individual patients. Community acceptance of the use of these
electronic records necessitates transparent rules for secondary use
of the records, with these rules being understood by the
community.
Electronic health records have also been integrated in the clas-
sical infectious disease risk assessment paradigm, which has been
adapted to take advantage of big data sets and bioinformatic
analytical tools. This approach has been demonstrated through
analysis of records of US Medicare beneﬁciaries to determine the
relative effectiveness of different inﬂuenza vaccines (Izurieta et al.,
2015). The successful study of a large population group demon-
strated differential effectiveness of the vaccines in older individuals
covered byMedicare, and identiﬁed for the ﬁrst time that inﬂuenza
related hospital admissions were signiﬁcantly reduced for speciﬁc
vaccines. A second example is examination of adverse events in
infants in response to vaccination with the second-generation
rotavirus vaccine (Yih et al., 2014). The large number of infants in
the study (approx. 1.2 million) provided sufﬁcient statistical power
to determine a low frequency adverse event that had not been
detected in earlier relatively large studies involving about 60,000
infants.
These examples demonstrate successful application of bioin-
formatics to provide new information for regulatory decision
makers. However, studies to date emphasize the importance of
capturing metadata in a structured way and adequate cross linking
of the metadata to the experimental data, such as adverse events,
medical records, and outcomes of outbreak investigations.
M.J. Healy et al. / Regulatory Toxicology and Pharmacology 80 (2016) 342e347 3454. Food safety and microbial genomics
Leading edge genomics technologies are opening new regula-
tory possibilities for comprehensive analyses of a variety of mi-
crobes, including those recovered from food inspection samples.
Whole genome sequencing (WGS) is now making it feasible to
sequence food-borne isolates in real-time, such as during food-
borne illness outbreak investigations (Elkins et al., 2013).
Sequencing pathogenic bacteria, whether in the context of
outbreak investigations or information gathering in the course of
research, can yield an unprecedented quality of information
regarding the relatedness of isolates and the presence of virulence
and other marker genes of relevance to pathogen identiﬁcation and
risk characterization. Such advances are resulting in the integration
of WGS approaches into food microbiology regulatory decision
making, although effective implementation requires a mechanism
to rapidly collate, analyse and report information from distributed
sources (Lambert et al., 2015).
One example, the Center for Genomic Epidemiology (Lyngby,
Demark, www.genomicepidemiology.org) focuses on WGS of bac-
terial pathogens and particularly how to assemble process and
handle the large amount of data generated in a standardized way
that will make the information useful, especially for diagnostic and
surveillance purposes. The Center employs a range of analytical
tools to identify certain phenotypes, such as acquired antimicrobial
resistance genes, virulence genes, various typing functions and the
development of phylogenetic trees using different data types. It
establishes processes for use of WGS in outbreak investigations and
clinical settings, thereby demonstrating how the data can be
practically applied, as well as contributing to the development of a
global system for microbiological identiﬁcation and epidemiolog-
ical surveillance.
Another example is related to the application genomic and
bioinformatics analyses to the variable global incidence of food
borne disease associatedwith contamination by E. coli 0157, amajor
food borne pathogen. The phylogenetic linkages of a collection of
isolates from geographically distinct regions, namely Argentina, the
United States and Australia, have been further reﬁned based on
molecular typing and the relationship between Shiga toxin genes
(stx) subtypes and total Shiga toxin production. Examination of
isolates revealed strong geographical segregation of Single Nucle-
otide Polymorphisms (SNPs) lineages, and several new lineages
were identiﬁed that are regionally distinct. Furthermore, there are
strong associations between speciﬁc SNP lineages, stx subtype and
stx production (Mellor et al., 2015). The regional distribution of
these lineages are correlated with regional differences in E. coli
0157 disease incidence, suggesting that these subtype differences
inﬂuence the patterns of disease seen in each location.
Studies of pathogenic E. coli have also highlighted some of the
challenges in metagenomic analyses. Different enrichment pro-
cedures and analytical tools can result in signiﬁcant differences in
determining phylogenetic diversity, intraspecies diversity and
marker abundance, highlighting the need for caution in the inter-
pretation and the conduct of multiple independent methods.
Metagenomics has emerged as an important area to understand the
interactions of the human microbiome and host to unravel the
complex relationship between the composition of the microbiome
and human health. The human microbiome, estimated to consist of
100 trillion bacterial cells, varies in its composition at different sites
of the body. The gut microbiota is considered the largest and most
complex, with many aspects of the host (e.g. age, diet, genetics)
inﬂuencing the microbial ecology. Clearly, the application of ge-
nomics and bioinformatics to determining the phylogeny of gut
microﬂora and high resolution microbiota proﬁling and linking
changes to health status is the focus of evermore attention, andwillundoubtedly lead to new therapeutic approaches.
However, these techniques are also being applied to food safety
risk assessment questions such as the role of residues of antimi-
crobial veterinary drugs in food products contributing to resistance
to clinically important antibiotics. The impact of residual levels of
antimicrobials in food on the bacteria and selection of resistant
bacteria in the gastrointestinal tract has not been fully understood,
although is now being elucidated through genomic and bio-
informatic analysis of the microbiome in individuals treated with
varying concentrations of antimicrobials. These studies are
demonstrating in greater clarity that both the relative abundance of
species in the gut and expression of resistance genes change in
response to antimicrobial use.
5. Computational toxicology and its role in regulatory
decision-making
Recent development in the tools and applications of predictive
toxicology is also signiﬁcantly changing theway inwhich the risk of
adverse events is assessed for chemicals used as drugs, added to
food and used in other contexts. One of the methodological ap-
proaches, Quantitative Structure-Activity Relationships (QSARs) is a
well-established multi-disciplinary methodology that integrates
biological, chemical and computational models to provide a new
paradigm for chemical risk assessment (Sturla et al., 2014). QSARs
therefore provide models for considering the standards for use of
predictive toxicology in regulatory decision making.
Barriers to the acceptance of QSARs in regulatory settings range
from scientiﬁc concerns (e.g., relevance, reliability and interpret-
ability), practical considerations (e.g., availability and ease of use,
portability/interoperability), to policy change that permits incor-
poration of QSARs in a modern toxicological framework with
comprehensive assessment and credible outcomes. These barriers
have been addressed through the initiatives of regulatory agencies
and multilateral bodies. Scientiﬁc concerns have been addressed
for the use of QSARs through the development of internationally
accepted reporting formats for models and predictions and guid-
ance on how to interpret the prediction results. For example,
guidance on use of QSARs in pesticide assessments, the grouping of
chemicals and the reporting of read-across and chemical categories
(e.g., OECD, 2014) have been established. The practical use of QSAR
is supported by freely available software tools and training, such as
the ChemoTyper application, which allows for searching and
highlighting chemical chemotypes (chemical substructures or
subgraphs) in datasets of molecules, and the Joint Research Centre
model database. Validation of different software packages, how-
ever, remains an issue. Finally the positioning of QSARs as part of an
integrated framework to testing and assessment should enable
QSAR to be used in concert with other strategies.
6. Data integrity, security and standards
6.1. Data integrity and security
The data sources to underpin personalizedmedicine, such as the
genetic basis of disease and the variation in pertinent genetic fac-
tors, health information from electronic records held by hospitals
andmedical practitioners and health related information generated
through mobile personal devices, are becoming available. Many of
these sources of information pose new, confronting and unresolved
challenges that have not been appropriately addressed; they
include data integrity, traceability, accuracy and security. A clear
example is the hackabilty of medical devices (http://go.bloomberg.
com/tech-blog/2012-02-29-hacker-shows-off-lethal-attack-by-
controlling-wireless-medical-device/http://go.bloomberg.com/
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ling-wireless-medical-device/). For example, the growing popu-
larity of the Internet of Things (IoT) crosses multiple industries and
disciplines. (The Internet of Things is the network of physical ob-
jects that contain embedded technology to communicate and sense
or interact with their internal states or the external environment.)
However, the Quantiﬁed Self movement and mobile medical care
raise similar big data concerns relating to hacking, data reliability,
privacy anonymity, data standardization, usability, reusability, and
interoperability of the data.
The Quantiﬁed Self movement seeks to use proprietary wear-
ables, smartphones, and other sensor technologies to collect,
analyze and quantify basic aspects of daily lives. Applications range
from collection of health related information by consumer products
to the academic effort to catalogue all available personal ‘omic data’
(e.g., the Snyderome). Often consumer-facing apps, falling outside
regulatory oversight, collect data using variable brands of sensors
running on hundreds of different types of smartphones with
thousands of different operating system conﬁgurations. This vari-
ability may result in unreliable and noisy data that are of ques-
tionable utility in monitoring and treating chronic disease.
Similarly, remote medical care, including telemedicine, and
particularly chronic disease management, intends to employ
smartphones, sensors, and third party devices to track and assess
the health of patients. Often this software is conﬁgured to report
back to health care professionals, especially when emergency
medical intervention is needed. Without strong encryption, sensor
data in transit can be hijacked, and unencrypted Wi-Fi enabled
medical devices can be maliciously manipulated.
One possible solution is implementation of middleware, a third
party gateway between the consumer/patient and the end-point
data analysis. The gateway could provide encryption and calibra-
tion services, and conﬁrm that data are standardized. The mid-
dleware would reject the data if key conditions are not fulﬁlled.
Moreover, a consumer could track their personal information to
assess to whom and where their data is transferred. Such an
approach allows for self-regulation to provide technological op-
tions to assure that the data are safely transferred and are usable,
reusable, transferable, and accessible.
Automated data gathering technologies, such as those used with
imaging techniques, are resulting in huge amounts of data being
gathered and integrated to inform clinical research and medical
practice. One of the major challenges in developing beneﬁcial ap-
plications from this knowledge is access to validated tools to assist
analysis of information, access to expertise to interrogate and
integrate multiple data sets, mechanisms to share information, and
mechanisms to classify and archive the information. The required
expertise, tools and computing power are largely being housed
within major institutions such as the European Molecular Biology
Laboratory e European Bioinformatics Institute (EMBL-EBI, http://
www.ebi.ac.uk/). The role of these institutions is continuing to
evolve with new types of data sets being added, for example NGS
data on human gene variation; images; and medical data.
However, there are ongoing challenges to facilitate effective use
of the data, particularly because of the diverse range of user com-
munities, need to integrate different types of data; the requirement
for establishing mechanisms and tools for data sharing; and for
providing secure environments for data analysis. The importance of
these institutions in facilitating the translation of data to infor-
mation for health care application is illustrated by the EMBL-EBI.
EMBL-EBI as an international and data sharing organization has a
rich history of successful partnerships with clinical researchers and
occasionally healthcare professionals. It has developed a coherent
strategy for medicine to focus on data that are open, research-
based, health-care-system agnostic and relevant to human health.EMBL-EBI is also a major driver for the pan European research
infrastructure for biological information, ELIXIR, and contributes to
the goal of accelerating the potential of genomic medicine to
advance human health through its membership in the Global
Alliance for Global Health (https://genomicsandhealth.org/).
6.2. Data standards and ontology
The large quantities of data generated by technologies such as
NGS and predictive toxicology are often still not managed effec-
tively, despite signiﬁcant investment. While it is recognized that
data should be ﬁndable, accessible, interoperable and reusable, in
practice, data are usually difﬁcult to ﬁnd and understand (e.g.,
Sansone and Rocca-Serra, 2012). A diverse range of organizations
are involved in developing content standards that describe data
better, but the multiple programs have resulted in a plethora of
standards. One tool that assists in navigating and selecting content
standards is a web-based, curated and searchable registry that
ensures standards and databases are registered, informative and
discoverable. It also monitors development and evolution of stan-
dards, their use in databases and adoption of both in data policies
(https://biosharing.org/pages/about/).
However, there remain signiﬁcant inadequacies in the devel-
opment of content standards, which are now being addressed
through major initiatives, such as the European Innovative Medi-
cines Initiative, the pan-European infrastructure for biological in-
formation (Elixir programme) and the National Institutes of Health
Big Data to Knowledge initiative (http://www.imi.europa.eu;
https://www.elixir-europe.org/about/elixir-programme-2014-
2018; https://datascience.nih.gov/bd2k). These initiatives focus on
best practice data storage, analysis and use that ultimately should
improve accessibility and usability of the data being generated.
7. Discussion
Personalized and precision medicine are the wave of the future,
where bioinformatics plays a signiﬁcant role. Signiﬁcant resources
are being devoted to realizing the regulatory potential of these
approaches that involve cross sector collaborations and multi-
disciplinary approaches. A range of data sources are being exploi-
ted in the development of these approaches, such as electronic
health records, patient data, administrative, genomic sequences,
meta-data, and predictive toxicology. Similarly, regulatory bioin-
formatics is modernizing approaches to food safety. Its use can
drastically decrease the time taken to identify a pathogen and in-
crease the efﬁciency and precision of risk characterizations. WGS
and bioinformatics can be integrated into food safety regulatory
decision making in a variety of ways, including species identiﬁca-
tion, virulence proﬁling, serotyping and molecular typing, signa-
ture sequences analysis, risk and phylogenetic proﬁling,
comprehensive information analysis and antimicrobial resistance
proﬁling. In a number of these applications, proof of concept has
been demonstrated and there is sufﬁcient conﬁdence in the
reproducibility and quality assurance procedures for use in regu-
latory applications.
There are many different types of big data sets and the power of
analysis and data mining comes from the analysts ability to inte-
grate many different layers of datasets for the synthesis of new
information. Big data can include both structured and unstructured
data sets and these can be records with narratives and descriptors
and databases of reports of adverse effects and each database
typically develops its own lexicons and rules. In order to support
good regulatory decision making, datasets must be of good quality,
robust, veriﬁed and have sufﬁcient metadata.
Big data pose new regulatory challenges and requires new skill
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to computer and data analysis expertise, key skill sets include a
basic understanding of risk analysis integrated with statistical
knowledge. Big data analysis can be used for the individual risk
assessments elements; dose response using databases (GenBank,
EMBL, Electronic Health Records, Administrative Records); expo-
sure (sources, contamination, potential for growth and the internet
of things); and risk characterization (distribution curves, millions of
iterations and simulations, visualization tools).
To fully reap the beneﬁts of the emerging use of bioinformatics
across a broad range of data sets and provide a robust basis for
regulatory decision making, a number of challenges must continue
to be addressed. There is an urgent need for standards and vali-
dation processes that are applicable internationally. Data must be
appropriately stored and be shared and accessible. The challenges
of integrating big data sets that have different degrees of data
integrity and standardization and application of different software
and computational methods must be resolved. These issues high-
light the important role of broad based international collaborations
and projects in achieving international consensus.
The use of certain data sets for health and medical purposes
raise signiﬁcant privacy and ethical issues, for example electronic
health records. Patient consent may be required in some cases and
there is a risk that biases occur in the datasets if subsets of patients
decline to allow their personal information to be used. As indi-
vidual patient data may have implications for family members,
ethical issues also arise.
Finally, big data repositories are growing exponentially and in
some cases faster than knowledge of the basic biology underpin-
ning the science and biological relevance of the data. The challenge
remains in our ability to interpret the meaning of the data and
synthesize relevant information and knowledge so it can be effec-
tively applied to deliver improved health outcomes and sound
regulatory decisions for our communities.
In summary, regulatory bioinformatics offers exciting possibil-
ities for developing targeted medicine and therapeutics as well as
post market monitoring of the safety of medical products and food.
There have been a limited number of applications of these tech-
nologies, which have demonstrated the enormous potential health
beneﬁts of the future. However, there remain challenges for regu-
latory bioinformatics with respect to quality, accessibility, security,
transparency, accountability and integrity. The feasibility of devel-
oping a standard for both bioinformatics analysis and reporting of
new data stream to assure the reliability of processes used in
deriving critical regulatory information is being discussed in
GSRS2015. At the time of this writing, the technical Working Group
on Bioinformatics governed by GCRSR has undertaken two key
bioinformatics gap analyses for regulatory uptake of genomic in-
formation including comparison of existing standards and best
practice elements (e.g., ﬁtness for purpose, traceability, auditability
and documentation). This practice will further our knowledge to
develop robust regulatory bioinformatics framework for enhanced
application of emerging technologies in regulatory decision-
making.
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